The Impact of Dexamethasone on Short- and Long-term Mortality in Hospitalized COVID-19 Patients: a Retrospective Study

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Nov 26

PMID 39587481

Authors

Jian Zhao

Hui Hua Jiang

Hong Hong Wan

Dan Liu

Yi Zhao

Yan Qing Chen

Yuan Zhuo Chen

Affiliations

Soon will be listed here.

Abstract

Background: Dexamethasone has been widely used in treating severe COVID-19 patients due to its anti-inflammatory properties. However, its long-term impact on mortality remain unclear.

Objective: To evaluate the effect of dexamethasone on short-term (28-day) and long-term (1-year) mortality in hospitalized COVID-19 patients and to explore its efficacy across different respiratory support.

Methods: A retrospective cohort study was conducted using the MIMIC-IV (v3.0) database. A total of 576 confirmed COVID-19 patients were included, with 288 patients receiving dexamethasone and 288 not receiving it, matched by propensity scores. Survival analyses assessed the impact of dexamethasone on mortality, and subgroup analyses were performed based on the type of respiratory support received.

Results: After propensity score matching, dexamethasone treatment was associated with reduced mortality at both 28 days (adjusted HR 0.67, 95% CI 0.46-0.99, P = 0.045) and 1 year (adjusted HR 0.66, 95% CI 0.47-0.92, P = 0.014). Subgroup analysis revealed differential treatment effects by respiratory support type (P for interaction = 0.001 at 28 days and 0.004 at 1 year). The survival benefit was most pronounced in patients receiving NIV (28-day adjusted HR 0.15, 95% CI 0.05-0.42, P < 0.001) and significant in those receiving IMV (28-day adjusted HR 0.62, 95% CI 0.39-0.99, P = 0.045), while no significant benefit was observed in patients receiving oxygen therapy alone.

Conclusion: This retrospective study suggests that dexamethasone treatment was associated with reduced mortality in hospitalized COVID-19 patients, particularly in those receiving NIV or IMV. These findings add to the evidence supporting dexamethasone use in severe COVID-19 patients requiring respiratory support.

References

Issak E, Amin M . Timing of corticosteroids in non-severe non-hospitalized COVID-19 patients: open-label, two-center, randomized controlled study (TICS-COV19 study). Korean J Intern Med. 2023; 38(2):207-217. PMC: 9993104. DOI: 10.3904/kjim.2022.232. View

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

Tomazini B, Maia I, Cavalcanti A, Berwanger O, Rosa R, Veiga V . Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020; 324(13):1307-1316. PMC: 7489411. DOI: 10.1001/jama.2020.17021. View

Sterne J, Murthy S, Diaz J, Slutsky A, Villar J, Angus D . Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020; 324(13):1330-1341. PMC: 7489434. DOI: 10.1001/jama.2020.17023. View

Ye X, Li Y, Luo F, Xu Z, Kasimu K, Wang J . Efficacy and safety of glucocorticoids in the treatment of COVID-19: a systematic review and meta-analysis of RCTs. Clin Exp Med. 2024; 24(1):157. PMC: 11246314. DOI: 10.1007/s10238-024-01405-0. View

Bahl A, Johnson S, Chen N . Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients. Intern Emerg Med. 2021; 16(6):1593-1603. PMC: 7864133. DOI: 10.1007/s11739-021-02655-6. View

Kow C, Ramachandram D, Hasan S . Intermediate- to high-dose dexamethasone versus low-dose dexamethasone in patients with COVID-19 requiring respiratory support: a systematic review and meta-analysis of randomized trials. Inflammopharmacology. 2023; 31(5):2773-2779. PMC: 10236382. DOI: 10.1007/s10787-023-01251-8. View

Fadel R, Morrison A, Vahia A, Smith Z, Chaudhry Z, Bhargava P . Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19. Clin Infect Dis. 2020; 71(16):2114-2120. PMC: 7314133. DOI: 10.1093/cid/ciaa601. View

Villar J, Ferrando C, Martinez D, Ambros A, Munoz T, Soler J . Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020; 8(3):267-276. DOI: 10.1016/S2213-2600(19)30417-5. View

10.

Maskin L, Bonelli I, Olarte G, Palizas Jr F, Velo A, Lurbet M . High- Versus Low-Dose Dexamethasone for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome: A Multicenter, Randomized Open-Label Clinical Trial. J Intensive Care Med. 2021; 37(4):491-499. PMC: 8926919. DOI: 10.1177/08850666211066799. View

11.

Taboada M, Rodriguez N, Varela P, Rodriguez M, Abelleira R, Gonzalez A . Effect of high low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial. Eur Respir J. 2021; 60(2). PMC: 8678498. DOI: 10.1183/13993003.02518-2021. View

12.

Zhang G, Su L, Wu W, Qiao Q, Gao S, Zhang Y . Efficacy of different doses of corticosteroids in treating severe COVID-19 pneumonia. Virol J. 2024; 21(1):74. PMC: 10967132. DOI: 10.1186/s12985-024-02345-7. View

13.

Liu J, Zhang S, Dong X, Li Z, Xu Q, Feng H . Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. J Clin Invest. 2020; 130(12):6417-6428. PMC: 7685724. DOI: 10.1172/JCI140617. View

14.

Johnson A, Pollard T, Shen L, Lehman L, Feng M, Ghassemi M . MIMIC-III, a freely accessible critical care database. Sci Data. 2016; 3:160035. PMC: 4878278. DOI: 10.1038/sdata.2016.35. View

15.

Alhazzani W, Moller M, Arabi Y, Loeb M, Gong M, Fan E . Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med. 2020; 48(6):e440-e469. PMC: 7176264. DOI: 10.1097/CCM.0000000000004363. View

16.

Sun G, Lin K, Ai J, Zhang W . The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID: a systematic review and meta-analysis. Clin Microbiol Infect. 2024; 30(12):1505-1513. DOI: 10.1016/j.cmi.2024.07.006. View

17.

Richards G, Feldman C . The use of corticosteroids for COVID-19 infection. Afr J Thorac Crit Care Med. 2021; 26(3). PMC: 7346767. DOI: 10.7196/AJTCCM.2020.v26i3.106. View